Nguyen Quang, Dominguez Joann, Nguyen Loida, Gullapalli Nageshwara
Assistant Professor, Department of Endocrinology, Diabetes, and Metabolism, University of Nevada School of Medicine, Reno.
Internal Medicine Resident, California Pacific Medical Center, San Francisco.
Am Health Drug Benefits. 2010 Jan;3(1):47-56.
Hypertension is a significant and costly public health problem. It is a major, but modifiable contributor for the development of cardiovascular disease. Randomized controlled trials have shown that controlling hypertension reduces the risk of stroke, coronary artery disease, congestive heart failure, end-stage renal disease, peripheral vascular disease, as well as overall mortality. The risk of developing these hypertension-related complications is continuous, starting at a blood pressure level as low as 115/75 mm Hg. Despite the inherent health risks associated with uncontrolled hypertension, elevated blood pressure remains inadequately treated in the majority of patients. This article reviews guidelines for optimal evaluation of hypertension and current therapeutic options available to combat this common yet pervasive disease.
高血压是一个严重且代价高昂的公共卫生问题。它是心血管疾病发生的主要但可改变的因素。随机对照试验表明,控制高血压可降低中风、冠状动脉疾病、充血性心力衰竭、终末期肾病、外周血管疾病以及总体死亡率的风险。从低至115/75毫米汞柱的血压水平开始,发生这些与高血压相关并发症的风险就是持续存在的。尽管未控制的高血压存在内在健康风险,但大多数患者的血压升高仍未得到充分治疗。本文综述了高血压最佳评估指南以及对抗这种常见且普遍存在疾病的当前治疗选择。